Aminorex

Quality 0.50 · 1 view · Updated 2 months ago

Chemical compound

title: "Aminorex" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["5-ht2b-agonists", "5-ht2c-agonists", "aminorexes", "anorectics", "cardiotoxins", "norepinephrine-dopamine-releasing-agents", "recreational-drug-metabolites", "respiratory-toxins", "stimulants", "withdrawn-drugs"] description: "Chemical compound" topic_path: "general/5-ht2b-agonists" source: "https://en.wikipedia.org/wiki/Aminorex" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Chemical compound ::

| Watchedfields = changed | verifiedrevid = 447552025 | image = Aminorex structure.svg | image_class = skin-invert-image | alt = Skeletal formula | image2 = Aminorex molecule ball.png | image_class2 = bg-transparent | alt2 = Ball-and-stick model of aminorex | chirality = Racemic mixture

| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | routes_of_administration = Oral | class = Stimulant; Appetite suppressant; Norepinephrine–dopamine releasing agent | ATC_prefix = None | ATC_suffix =

| legal_AU = | legal_BR = B2 | legal_BR_comment = | legal_CA = Schedule III | legal_UK = Class C | legal_US = Schedule I | legal_DE = Anlage II

| bioavailability = | protein_bound = | metabolism = | onset = | elimination_half-life = | duration_of_action = | excretion =

| CAS_number_Ref = | CAS_number = 2207-50-3 | PubChem = 16630 | DrugBank_Ref = | DrugBank = DB01490 | ChemSpiderID_Ref = | ChemSpiderID = 15767 | UNII_Ref = | UNII = 2SH16612I9 | KEGG_Ref = | KEGG = D02909 | ChEMBL_Ref = | ChEMBL = 106258 | synonyms = Aminoxaphen; Aminoxafen; McN-742

| IUPAC_name = (RS)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine | C=9 | H=10 | N=2 | O=1 | SMILES = NC1=NCC(C2=CC=CC=C2)O1 | StdInChI_Ref = | StdInChI = 1S/C9H10N2O/c10-9-11-6-8(12-9)7-4-2-1-3-5-7/h1-5,8H,6H2,(H2,10,11) | StdInChIKey_Ref = | StdInChIKey = SYAKTDIEAPMBAL-UHFFFAOYSA-N

Aminorex, sold under the brand names Menocil and Apiquel among others, is a weight loss (anorectic) stimulant drug. It was withdrawn from the market after it was found to cause pulmonary hypertension (PPH). In the United States, aminorex is a Schedule I controlled substance.

Aminorex, in the 2-amino-5-aryloxazoline group, was developed by McNeil Laboratories in 1962. It is closely related to 4-methylaminorex (4-MAR). Aminorex has been shown to have locomotor-stimulant effects, lying midway between dextroamphetamine and methamphetamine. Aminorex effects have been attributed to the release of catecholamines. It can be produced as a metabolite of the deworming medication levamisole, which is very frequently used as a cutting agent of illicitly produced cocaine.

Medical uses

Aminorex was formerly used as an appetite suppressant.

Pharmacology

Pharmacodynamics

Aminorex is a serotonin–norepinephrine–dopamine releasing agent (SNDRA). Its values for induction of monoamine release are 26.4nM for norepinephrine, 49.4nM for dopamine, and 193nM for serotonin. In addition to its monoamine-releasing activity, aminorex is a weak agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. Its EC50 values for activation of these receptors are 4,365nM for 5-HT2A, 870nM for 5-HT2B, and 525nM for 5-HT2C.

::data[format=table title="{{Nowrap|[[Monoamine releasing agent|Monoamine release]] of [[aminorex]] and related agents ({{Abbrlink|EC50|Half maximal effective concentration}}, nM)}}"]

CompoundRef
Phenethylamine10.9
Dextroamphetamine6.6–10.2
Dextromethamphetamine12.3–14.3
Aminorex15.1–26.4
cis-4-MAR4.8
cis-4,4'-DMAR11.8–31.6
trans-4,4'-DMAR31.6
cis-MDMAR14.8
trans-MDMAR38.9
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. The assays were done in rat brain synaptosomes and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Refs:
::

Activation of serotonin 5-HT2B receptors by aminorex, either directly via agonism or indirectly via serotonin release, has been implicated in the development of pulmonary arterial hypertension and cardiac valvulopathy with the drug. However, its EC50 for serotonin 5-HT2B receptor activation is 33-fold higher than its EC50 value for induction of norepinephrine release and is almost 50-fold less potent than the serotonin 5-HT2B receptor agonism of dexnorfenfluramine. This seems to call into question the role of direct agonism of the serotonin 5-HT2B receptor in the toxicity of aminorex. Along similar lines, chlorphentermine, a related drug that has also been associated with such adverse effects, shows negligible direct serotonin 5-HT2B receptor agonistic activity. However, it is possible that metabolites of aminorex and chlorphentermine might be more potent in this action.

Aminorex does not appear to have been assessed at the trace amine-associated receptor 1 (TAAR1). However, several derivatives of aminorex, such as 4-methylaminorex (4-MAR) and 4,4'-dimethylaminorex (4,4'-DMAR), have been found to be inactive at the mouse and rat TAAR1. Many other monoamine releasing agents (MRAs), such as many amphetamines, are rodent and/or human TAAR1 agonists. Activation of the TAAR1 may auto-inhibit and thereby constrain the monoaminergic effects of these agents. Lack of TAAR1 agonism in the case of aminorex analogues might enhance their effects relative to MRAs possessing TAAR1 agonism.

Chemistry

Aminorex is a member of the 2-amino-5-phenyloxazoline group. It is structurally related to the substituted amphetamines like amphetamine and to the substituted phenylmorpholines like phenmetrazine.

A variety of derivatives and analogues of aminorex are known. These include 2'-fluoro-4-methylaminorex (2F-MAR), 2C-B-aminorex, 3',4'-methylenedioxy-4-methylaminorex (MDMAR), 4'-bromo-4-methylaminorex (4B-MAR), 4'-chloro-4-methylaminorex (4C-MAR), 4'-fluoro-4-methylaminorex (4F-MAR), 4-methylaminorex (4-MAR), 4,4'-dimethylaminorex (4,4'-DMAR), clominorex, cyclazodone, fenozolone, fluminorex, pemoline, and thozalinone, among others.

Synthesis

The synthesis was first reported in a structure-activity relationship study of 2-amino-5-aryl-2-oxazolines, where aminorex was found to be approximately 2.5 times more potent than D-amphetamine sulfate in inducing anorexia in rats, and was also reported to have CNS stimulant effects.

::figure[src="https://upload.wikimedia.org/wikipedia/commons/a/aa/Aminorex_rxn_mech.png"] ::

The racemic synthesis involves addition/cyclization reaction of 2-amino-1-phenylethanol with cyanogen bromide. A similar synthesis has been also published. In a search for a cheaper synthetic route, a German team developed an alternative route which, by using chiral styrene oxide, allows an enantiopure product.

History

It was discovered in 1962 by Edward John Hurlburt, and was quickly found in 1963 to have an anorectic effect in rats. It was introduced as a prescription appetite suppressant in Germany, Switzerland and Austria in 1965, but was withdrawn in 1972 after it was found to cause pulmonary hypertension in approximately 0.2% of patients, and was linked to a number of deaths.

References

References

  1. Anvisa. (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
  2. (2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer US.
  3. (2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Netherlands.
  4. (November 2000). "Recreational use of aminorex and pulmonary hypertension". Chest.
  5. "2-Amino-5-Aryloxazoline Products".
  6. (Jan 1991). "Aminorex to fen/phen: an epidemic foretold". Circulation.
  7. (April 2009). "Aminorex and rexamino as metabolites of levamisole in the horse". Analytica Chimica Acta.
  8. (July 2011). "Determination of aminorex in human urine samples by GC-MS after use of levamisole". Journal of Pharmaceutical and Biomedical Analysis.
  9. (July 2002). "Therapeutic and adverse actions of serotonin transporter substrates". Pharmacol Ther.
  10. (2006). "Therapeutic potential of monoamine transporter substrates". Curr Top Med Chem.
  11. (April 2002). "Serotonin releasing agents. Neurochemical, therapeutic and adverse effects". Pharmacol Biochem Behav.
  12. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence.
  13. (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines".
  14. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse.
  15. (March 2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology.
  16. (July 2008). "Dopamine Transporters: Chemistry, Biology and Pharmacology". Wiley.
  17. (1999). "Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc".
  18. (April 2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology.
  19. (2014). "Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni')". Drug Testing and Analysis.
  20. (July 2015). "Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3',4'-methylenedioxy-4-methylaminorex (MDMAR)". Drug Testing and Analysis.
  21. (October 2003). "Monoamine transporters and psychostimulant drugs". European Journal of Pharmacology.
  22. (2000). "Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects". Drug Development Research.
  23. "PDSP Database".
  24. (2001). "BindingDB BDBM85705 Aminorex::CAS_2207-50-3::NSC_16630". Synapse (New York, N.Y.).
  25. (October 2018). "DARK Classics in Chemical Neuroscience: Aminorex Analogues". ACS Chem Neurosci.
  26. (August 2018). "The psychostimulant (±)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters". Neuropharmacology.
  27. (May 2019). "Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR". Neurotoxicology.
  28. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther.
  29. (July 2018). "Trace Amines and Their Receptors". Pharmacol Rev.
  30. (May 1963). "2-Amino-5-aryl-2-oxazolines. Potent New Anorectic Agents.". Journal of Medicinal Chemistry.
  31. (January 2004). "4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor". Bioorganic & Medicinal Chemistry Letters.
  32. "2-Amino-5-phenyl-2-oxazoline preparation".
  33. "2-amino-5, 6-dihydro-4ii-1, 3-oxazines and a process for their preparation".
  34. (June 2003). "Pharmacological therapy of obesity: past, present, and future". The Journal of Clinical Endocrinology and Metabolism.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

5-ht2b-agonists5-ht2c-agonistsaminorexesanorecticscardiotoxinsnorepinephrine-dopamine-releasing-agentsrecreational-drug-metabolitesrespiratory-toxinsstimulantswithdrawn-drugs